NASDAQ:WINT Windtree Therapeutics (WINT) Stock Price, News & Analysis $0.02 0.00 (-11.94%) As of 11:37 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock About Windtree Therapeutics Stock (NASDAQ:WINT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Windtree Therapeutics alerts:Sign Up Key Stats Today's Range$0.02▼$0.0250-Day Range$0.01▼$0.0352-Week Range$0.01▼$1.86Volume55,739 shsAverage Volume402,850 shsMarket Capitalization$796.29 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Windtree Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative therapies for acute cardiovascular and pulmonary conditions. The company leverages its proprietary KL4 surfactant technology to address diseases marked by surfactant deficiency or dysfunction, with a primary focus on acute respiratory distress syndrome (ARDS) in adults and respiratory distress syndrome (RDS) in premature infants. The company’s lead platform comprises synthetic peptide‐based surfactants designed to restore lung function by reducing surface tension in the alveoli. Windtree’s pipeline includes aerosolized and intratracheal formulations intended for rapid distribution in the lung, including programs that have advanced through preclinical studies and early-stage clinical trials. These programs aim to offer an alternative to animal-derived surfactants and to target patient populations with significant unmet medical needs. Headquartered in Warrington, Pennsylvania, Windtree collaborates with academic research centers and clinical investigators across the United States and Europe to conduct its development programs. The company’s activities encompass formulation optimization, toxicology testing, and multi-site clinical evaluations, supported by partnerships that extend its reach into critical care and neonatal intensive care settings. Under the leadership of President and CEO Michael Ott, Windtree maintains a management team with extensive experience in drug development, regulatory affairs and commercial strategy. The organization is committed to advancing its pipeline through regulatory interactions and clinical milestones in pursuit of therapies that can improve outcomes for patients with serious cardiopulmonary disorders.AI Generated. May Contain Errors. Read More Receive WINT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Windtree Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. WINT Stock News HeadlinesWindtree Therapeutics Delays Filing of Annual ReportApril 1, 2026 | tipranks.comCommLoan Achieves Nationwide Regulatory Approval Across All 50 StatesMarch 17, 2026 | prnewswire.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.May 8 at 1:00 AM | American Alternative (Ad)Windtree Therapeutics Announces Sudden Departure of President and COOJanuary 17, 2026 | theglobeandmail.comWindtree sells heart drug assets, keeps a cut of any future breakthroughDecember 30, 2025 | msn.comWindtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug CandidatesDecember 23, 2025 | finance.yahoo.comWindtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech SpaceDecember 4, 2025 | markets.businessinsider.comWindtree announces it has signed a letter of intent to acquire CommLoanDecember 4, 2025 | msn.comSee More Headlines WINT Stock Analysis - Frequently Asked Questions How have WINT shares performed this year? Windtree Therapeutics' stock was trading at $0.0320 at the start of the year. Since then, WINT shares have decreased by 44.7% and is now trading at $0.0177. How were Windtree Therapeutics' earnings last quarter? Windtree Therapeutics, Inc. (NASDAQ:WINT) issued its earnings results on Tuesday, August, 19th. The company reported ($3.06) EPS for the quarter, beating the consensus estimate of ($99.00) by $95.94. When did Windtree Therapeutics' stock split? Windtree Therapeutics shares reverse split on the morning of Friday, February 21st 2025.The 1-50 reverse split was announced on Tuesday, February 18th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Windtree Therapeutics? Shares of WINT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Windtree Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Windtree Therapeutics investors own include Plug Power (PLUG), Trevena (TRVN), SNDL (SNDL), AMC Entertainment (AMC), Sphere 3D (ANY), BioCardia (BCDA) and Sonnet BioTherapeutics (SONN). Company Calendar Last Earnings8/19/2025Today5/08/2026Next Earnings (Estimated)5/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:WINT CIK946486 Webwww.windtreetx.com Phone(215) 488-9300Fax215-488-9301Employees30Year Founded1992Profitability EPS (Trailing Twelve Months)($8.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-207.34% Return on Assets-50.19% Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book0.02Miscellaneous Outstanding Shares44,988,000Free Float3,656,000Market Cap$796.29 thousand OptionableNot Optionable Beta1.75 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:WINT) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | Sponsored‘Please’: OpenAI CEO Sam Altman Begs Small Company for HelpSpaceX 'Dark Energy' Replaces Foreign Oil For years, we've been told SpaceX is a rocket company. But accord...Altimetry | SponsoredIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Windtree Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
